Co-Diagnostics, Inc. (CODX) Earnings Call Transcripts

Co-Diagnostics, Inc.'s Latest Earnings Call - Q4 FY2025

In the fourth quarter and full year ended December 31, 2025, Co-Diagnostics, Inc. reported total revenue of $0.6 million, a significant decline from $3.9 million in 2024, primarily due to lower grant revenue. The net loss for the year was $46.9 million, or $35.25 per share, compared to a net loss of $37.6 million, reflecting an $18.9 million noncash impairment charge. Management maintained a focus on advancing their clinical pipeline and achieving regulatory milestones, indicating a strategic shift towards commercialization in 2026, with expectations for TB test commercialization in India by Q3 2026.

Reported metrics

Guidance from management

Management indicated a focus on advancing their clinical pipeline and achieving regulatory milestones, with expectations for TB test commercialization in India by Q3 2026. They also plan to continue evaluating financing alternatives to support growth.

What management said

Thank you, Brian. To close, I want to extend our sincere gratitude to our shareholders for their continued support and to our employees whose dedication and hard work remain one of our most important assets as we execute on the Co-Dx vision. We are focused on delivering against our strategy and advancing the company toward its next phase. With that, we will now open the line for questions. Operator?

Well, this -- when we do a study like that, this is something that we hire a CRO to do, and it's a very structured sort of clinical trial. The FDA knows what we're doing. They know how many samples that we're going to collect, and I would represent to you that it's in excess of 1,200 different patients that have already been through the enrollment. So we're nearing conclusion here of the entire test and getting ready...

What analysts pressed on

Analysts expressed concerns regarding the significant revenue decline and the implications of the increased net loss. There were questions about the timeline for regulatory submissions and the potential impact of ongoing operating losses on future growth.

Main topics on the call

• Revenue Decline — Co-Diagnostics reported total revenue of $0.6 million for 2025, down from $3.9 million in 2024, driven by lower grant revenue. Management stated, 'the year-over-year decrease was primarily driven by lower grant revenue a...
• Regulatory Progress in India — The company received a CDSCO license to manufacture the PCR Pro instrument in India, marking a key regulatory milestone. This supports their strategy to commercialize TB diagnostics in a market with significant demand, w...
• Increased Operating Expenses — Total operating expenses rose to $50.6 million in 2025 from $43.0 million in 2024, largely due to an $18.9 million noncash impairment charge. Excluding this charge, operating expenses showed a decline, reflecting a focus...
• Strategic Alternatives for CoSara — Co-Diagnostics is exploring strategic alternatives for its CoSara joint venture, including a potential SPAC transaction to support capital needs. Management noted, 'CoSara has reached a stage where it can stand on its ow...

Read the full Co-Diagnostics, Inc. transcript (Q4 FY2025) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 25 Co-Diagnostics, Inc. earnings call transcripts on record, spanning August 13, 2020 to May 14, 2026. Based on this history, Co-Diagnostics, Inc. reports quarterly. The most recent call on file is dated May 14, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

CODX

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

25

First call

August 13, 2020

Most recent

May 14, 2026

Reporting cadence

quarterly